Spyre Therapeutics Inc. – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: SYRE
Share price (6/2/26): $69.16
Market cap (6/2/26): $6.006 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

from S-1 132 pages Agreement and Plan of Merger by and Among: Aeglea Biotherapeutics, Inc., a Delaware Corporation; Aspen Merger Sub I, Inc., a Delaware Corporation; Sequoia Merger Sub II, LLC, a Delaware Limited Liability Company; and Spyre Therapeutics, Inc., a Delaware Corporation Dated as of June 22, 2023

from S-1/A 132 pages Agreement and Plan of Merger by and Among: Aeglea Biotherapeutics, Inc., a Delaware Corporation; Aspen Merger Sub I, Inc., a Delaware Corporation; Sequoia Merger Sub II, LLC, a Delaware Limited Liability Company; and Spyre Therapeutics, Inc., a Delaware Corporation Dated as of June 22, 2023

from 8-K 132 pages Agreement and Plan of Merger by and Among: Aeglea Biotherapeutics, Inc., a Delaware Corporation; Aspen Merger Sub I, Inc., a Delaware Corporation; Sequoia Merger Sub II, LLC, a Delaware Limited Liability Company; and Spyre Therapeutics, Inc., a Delaware Corporation Dated as of June 22, 2023